Ringing in the Dark: Why Macrolide Ototoxicity Belongs in Every Azithromycin Safety Review
Photo: U.S. Air Force photo by Andrea Jenkins, Public domain, via Wikimedia Commons
The Complaint That Never Reaches the Chart
A patient completes a five-day course of azithromycin for bronchitis and returns a few weeks later describing a faint ringing, or the sense that conversation happens behind glass. The clinician looks in the ears, sees no effusion, and attributes the symptom to resolving congestion. The note says nothing about hearing. Months later, an audiogram shows a bilateral high-frequency sensorineural loss that no one links to the prescription.
That sequence is not rare. It is the predictable result of a drug prescribed in enormous volume, tolerated well by most patients, and almost never discussed in the same breath as ototoxicity. Macrolide-associated hearing loss is a documented adverse effect, and azithromycin is not exempt. It deserves a routine line in the safety review.
What the Evidence Actually Shows
Azithromycin ototoxicity is not a theoretical concern. Case series and pharmacovigilance reviews describe bilateral sensorineural hearing loss, tinnitus, and vestibular symptoms, most often in three overlapping settings: high cumulative doses, prolonged courses, and impaired renal clearance. The immunomodulatory use of azithromycin — 250 mg three times weekly for months in COPD, cystic fibrosis, or diffuse panbronchiolitis — places patients in the first two categories at once. Standard five-day respiratory courses carry a much lower individual signal, but they are written so often that rare events become population-level events.
Recovery after discontinuation is the usual outcome, but it is neither immediate nor guaranteed. Audiometric improvement may lag weeks to months, and permanent loss has been reported. That variability is exactly why baseline and interval questioning matters more than retrospective attribution.
Three Mechanisms, One Vulnerable Organ
Macrolides distribute into inner ear fluids, and several mechanisms have been proposed for the injury that follows. Oxidative stress appears to damage cochlear hair cells. Disruption of ion transport in the stria vascularis alters the endocochlear potential. Inhibition of P-glycoprotein efflux may raise intracellular concentrations in vulnerable tissue. The common thread is dose and duration dependence, which is amplified when clearance falls.
Azithromycin is primarily eliminated by the liver, but renal impairment still appears repeatedly as a risk factor in reports. The likely explanations include accumulation of metabolites, comorbid exposure to other ototoxic agents, and the frailty that accompanies advanced kidney disease.
Who Is Most Vulnerable
The highest-risk groups are identifiable before the first dose:
- Adults older than 65, particularly those with pre-existing hearing loss or tinnitus
- Patients with eGFR below 30 mL/min/1.73 m2, including those on dialysis
- Anyone receiving azithromycin for more than four weeks, especially at immunomodulatory doses
- Patients taking loop diuretics, aminoglycosides, platinum-based chemotherapy, or high-dose salicylates
- Patients with prior head trauma, noise-induced hearing loss, or a history of ototoxic drug exposure
Age deserves special emphasis. Presbycusis is common, gradual, and bilateral — the same descriptors applied to drug-induced loss. The difference is tempo. A patient who reports a change over two weeks is not describing aging.
Separating Drug From Decongestion
The differential is wider than many clinicians assume:
- Cerumen impaction is typically unilateral and conductive, and it resolves with removal.
- Presbycusis evolves over years, is symmetric, and favors high frequencies.
- Eustachian tube dysfunction fluctuates with congestion and resolves as the infection clears.
- Drug-induced injury begins during or within weeks of therapy, is often bilateral, may include tinnitus or unsteadiness, and leaves the tympanic membrane looking normal.
Otoscopy is necessary but not sufficient. A normal tympanic membrane does not exclude sensorineural injury, and a patient with both eustachian tube dysfunction and early ototoxicity can be easily misclassified.
A Screening Routine That Fits a Busy Visit
At initiation of any course expected to exceed two weeks, ask about baseline hearing, tinnitus, and prior ototoxic exposure, and document the answers. At each interval visit, ask two questions: Have you noticed any change in your hearing? Any new ringing or imbalance? Repeat them at discontinuation.
For standard short courses, a single question at follow-up is reasonable. For patients on prolonged therapy, consider audiometry at baseline and again at three to six months, or sooner if symptoms emerge.
When symptoms appear, perform otoscopy and, if available, tuning fork testing. Audiometry is the reference standard. Depending on the indication, options include dose reduction, alternate-day dosing, or substitution with a non-macrolide agent.
Counseling Language That Works
Single sentences delivered at the right moment are more effective than a paragraph in a discharge packet:
- 'This antibiotic can occasionally affect hearing or cause ringing in the ears. If you notice muffled hearing, new tinnitus, or unsteadiness, call us before your next dose rather than waiting until the course is over.'
- 'Do not stop the antibiotic on your own if you have been told the course is essential. Call the office so we can decide together.'
- 'If you already have hearing aids or a known hearing loss, tell us now so we can set a baseline.'
Referral Triggers
Send for urgent evaluation when hearing loss is sudden and unilateral, when vertigo is accompanied by nystagmus or vomiting, or when symptoms persist beyond two weeks after discontinuation. Refer electively for asymmetric audiometric findings, for persistent tinnitus that interferes with sleep or work, and for any patient who needs to continue a macrolide despite new auditory symptoms. In that last scenario, audiology input should precede continuation, not follow it.
The Point Is Not Alarm
Ototoxicity should not deter appropriate azithromycin use. For many indications the drug remains a reasonable, even preferred, choice. But safety review is not limited to QT intervals and drug interactions. Hearing is part of the same review, and the questions that detect injury take less than thirty seconds to ask.